Serum Concentration of Asprosin in New-onset Type 2 Diabetes

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2020 Jul 28

PMID 32714446

Citations 26

Authors

Shakiba Naiemian

Mohsen Naeemipour

Mehdi Zarei

Moslem Lari Najafi

Ali Gohari

Mohammad Reza Behroozikhah

Hafez Heydari

Mohammad Miri

Affiliations

Soon will be listed here.

Abstract

Background: Asprosin, a newly identified adipokine, is pathologically increased in individuals with insulin resistance. However, the available evidence on the association of asprosin and type 2 diabetes mellitus (T2DM) status is still scarce. Therefore, this study aimed to determine the relationship between serum concentrations of asprosin and T2DM status.

Methods: This observational study was performed based on 194 adults (97 newly diagnosed T2DM and 97 healthy individuals). Anthropometric and biochemical variables were determined in all participants. Serum concentrations of asprosin were measured using enzyme-linked immunosorbent assay (ELISA).

Results: In patients with T2DM, the serum concentrations of asprosin were significantly higher than the healthy controls (4.18 [IQR: 4.4] vs. 3.5 [IQR: 1.85], P < 0.001). The concentrations of asprosin were significantly correlated with body mass index (BMI) and fasting blood glucose (FBG) in healthy subjects and with BMI, FBG, hemoglobin A1c (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), and quantitative insulin check index (QUICKI), triacylglycerol (TAG) and total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio in the T2DM group. In fully adjusted model, the odds ratio (OR) of T2DM with serum concentrations of asprosin was approximately 1.547 (95% CI 1.293-1.850, P < 0.001) compared to the control group. Multiple stepwise regression analysis indicated that FBG and HOMA-IR were independently associated with asprosin in T2DM.

Conclusion: Our findings indicated that serum concentrations of asprosin are increased in patients with T2DM. Also, asprosin is correlated with insulin resistance and TC/HDL-C ratio (atherosclerotic risk factor of cardiovascular diseases) in patients with T2DM.

Citing Articles

Relationship of asprosin and diabetes: a meta-analysis.

Zeng X, Sun X, He W, Xie J, Xin C BMC Endocr Disord. 2025; 25(1):15.

PMID: 39844112 PMC: 11756155. DOI: 10.1186/s12902-025-01843-1.

Asprosin is a Reliable Predictor of Osteoporosis in Type 2 Diabetic Postmenopausal Women: A Case-Control Study.

Roomi A, Ali E, Nori W, Rahmah M Indian J Clin Biochem. 2025; 40(1):97-104.

PMID: 39835234 PMC: 11741977. DOI: 10.1007/s12291-023-01163-y.

Metformin's impact on asprosin and FBN1 expression: Potential mechanisms beyond insulin sensitivity in type 2 diabetes in rats.

Dashtkar A, Karajibani M, Saravani M, Zanganeh R, Fanaei H Curr Res Pharmacol Drug Discov. 2025; 8():100207.

PMID: 39802821 PMC: 11721834. DOI: 10.1016/j.crphar.2024.100207.

Lack of correlation between asprosin serum levels and hyperphagic behavior in subjects with prader-Willi Syndrome.

Faienza M, Chiarito M, Aureli A, Buganza R, Corica D, Delvecchio M J Endocrinol Invest. 2024; .

PMID: 39636471 DOI: 10.1007/s40618-024-02511-2.

The Associations between Asprosine, Clusterin, Zinc Alpha-2-Glycoprotein, Nuclear Factor Kappa B, and Peroxisome Proliferator-Activated Receptor Gamma in the Development of Complications in Type 2 Diabetes Mellitus.

Senyigit A, Durmus S, Tabak O, Oruc A, Uzun H, Ekinci I J Clin Med. 2024; 13(20).

PMID: 39458076 PMC: 11508428. DOI: 10.3390/jcm13206126.

References

Khan U, Wang D, Sowers M, Mancuso P, Everson-Rose S, Scherer P . Race-ethnic differences in adipokine levels: the Study of Women's Health Across the Nation (SWAN). Metabolism. 2012; 61(9):1261-9. PMC: 3404256. DOI: 10.1016/j.metabol.2012.02.005. View

Wang Y, Rimm E, Stampfer M, Willett W, Hu F . Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005; 81(3):555-63. DOI: 10.1093/ajcn/81.3.555. View

Arabi Y, Jawdat D, Al-Dorzi H, Tamim H, Tamimi W, Bouchama A . Leptin, Ghrelin, and Leptin/Ghrelin Ratio in Critically Ill Patients. Nutrients. 2019; 12(1). PMC: 7020071. DOI: 10.3390/nu12010036. View

Groener J, Valkanou A, Kender Z, Pfeiffenberger J, Kihm L, Fleming T . Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PLoS One. 2019; 14(9):e0222771. PMC: 6752946. DOI: 10.1371/journal.pone.0222771. View

Zhang L, Chen C, Zhou N, Fu Y, Cheng X . Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2017; 489:183-188. DOI: 10.1016/j.cca.2017.10.034. View

Wang Y, Qu H, Xiong X, Qiu Y, Liao Y, Chen Y . Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion. Mediators Inflamm. 2018; 2018:9471583. PMC: 5883982. DOI: 10.1155/2018/9471583. View

Meshkini M, Alaei-Shahmiri F, Mamotte C, Dantas J . Ethnic Variations in Adiponectin Levels and Its Association with Age, Gender, Body Composition and Diet: Differences Between Iranians, Indians and Europeans Living in Australia. J Immigr Minor Health. 2018; 20(6):1362-1372. DOI: 10.1007/s10903-018-0706-9. View

Santoleri D, Titchenell P . Resolving the Paradox of Hepatic Insulin Resistance. Cell Mol Gastroenterol Hepatol. 2019; 7(2):447-456. PMC: 6369222. DOI: 10.1016/j.jcmgh.2018.10.016. View

Chen L, Magliano D, Zimmet P . The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives. Nat Rev Endocrinol. 2011; 8(4):228-36. DOI: 10.1038/nrendo.2011.183. View

10.

Wang M, Yin C, Wang L, Liu Y, Li H, Li M . Serum Asprosin Concentrations Are Increased and Associated with Insulin Resistance in Children with Obesity. Ann Nutr Metab. 2019; 75(4):205-212. DOI: 10.1159/000503808. View

11.

Li X, Liao M, Shen R, Zhang L, Hu H, Wu J . Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases. Mediators Inflamm. 2018; 2018:7375294. PMC: 6247534. DOI: 10.1155/2018/7375294. View

12.

Shi J, Fan J, Su Q, Yang Z . Cytokines and Abnormal Glucose and Lipid Metabolism. Front Endocrinol (Lausanne). 2019; 10:703. PMC: 6833922. DOI: 10.3389/fendo.2019.00703. View

13.

Arner P . Insulin resistance in type 2 diabetes -- role of the adipokines. Curr Mol Med. 2005; 5(3):333-9. DOI: 10.2174/1566524053766022. View

14.

Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J . Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med. 2001; 161(22):2685-92. DOI: 10.1001/archinte.161.22.2685. View

15.

Frithioff-Bojsoe C, Lund M, Lausten-Thomsen U, Hedley P, Pedersen O, Christiansen M . Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity. Pediatr Diabetes. 2019; 21(2):194-202. DOI: 10.1111/pedi.12964. View

16.

Carvalho M, Colaco A, Fortes Z . [Cytokines, endothelial dysfunction, and insulin resistance]. Arq Bras Endocrinol Metabol. 2006; 50(2):304-12. DOI: 10.1590/s0004-27302006000200016. View

17.

Kashino I, Nanri A, Kurotani K, Akter S, Yasuda K, Sato M . Association of dietary patterns with serum adipokines among Japanese: a cross-sectional study. Nutr J. 2015; 14:58. PMC: 4469003. DOI: 10.1186/s12937-015-0046-8. View

18.

Zhang X, Jiang H, Ma X, Wu H . Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig. 2019; 11(2):349-355. PMC: 7078095. DOI: 10.1111/jdi.13148. View

19.

Lee T, Yun S, Jeong J, Jung T . Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 2019; 486:96-104. DOI: 10.1016/j.mce.2019.03.001. View

20.

Li E, Shan H, Chen L, Long A, Zhang Y, Liu Y . OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin. Cell Metab. 2019; 30(2):319-328.e8. DOI: 10.1016/j.cmet.2019.05.022. View